Demet Turan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Demet Turan has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Efsun Gonca Uğur Chousein
Department of Pulmonology, Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital, University of Health Sciences, Istanbul, Türkiye
16 shared publications - Mehmet Akif Özgül
Basaksehir Cam and Sakura City Hospital, Department of Pulmonology, Istanbul, Turkey
16 shared publications - Erdoğan Çetinkaya
Department of Chest Disease, Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital, University of Health Sciences, Istanbul, Turkey
15 shared publications - Halit Çınarka
Department of Chest Diseases, University of Health Sciences, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkiye
8 shared publications - Binnaz Zeynep Yıldırım
Department of Chest Diseases, University of Health Sciences, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkiye
7 shared publications - Elif Tanrıverdi
Department of Pulmonology, Yedikule Pulmonary Diseases and Thoracic Surgery Education and Research Hospital, Istanbul, Turkey
7 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (46) , e51593
Changes in quality of life, sleep quality, and anxiety following tracheobronchial stenting in patients with central airway obstruction: A retrospective observational study
Central airway obstruction (CAO) severely impairs respiratory function and psychosocial well-being. This study evaluated the impact of tracheobronchial stenting on quality of life, sleep quality, and anxiety levels in patients with CAO. This retrospective observational study included 106 patients (63.2% male) who underwent tracheobronchial stenting between January and September 2024. Patients were assessed 1 day before and 1 month after the procedure using the Short Form-36, Beck Anxiety Inventory (BAI), and Pittsburgh Sleep Quality Index (PSQI). Significant improvements were observed in all Short Form-36 subscales ( P < .001), except for mental health ( P = .094). The largest improvement was observed in physical functioning, with median scores increasing from 22.5 to 80.0. Median BAI scores decreased from 38 to 22, and PSQI scores improved from 15 to 10 ( P < .001 for both). Effect size analysis demonstrated large improvements (Cohen dz = 1.110 for BAI and 1.555 for PSQI). Improvements were similar across malignant and benign (post-intubation tracheal stenosis) etiologies. Female patients demonstrated greater reductions in anxiety ( P = .005). Multivariate analysis identified age and educational level as independent predictors of anxiety change ( R 2 = 0.289, P < .001). Tracheobronchial stenting is associated with significant improvements in quality of life, sleep quality, and anxiety. These findings demonstrate that the clinical benefit of airway stenting extends beyond airway patency to include improvements in patient-centered outcomes, highlighting the importance of integrating psychosocial assessment into interventional pulmonology practice.
- 13 November 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (46) , e51593
Open AccessChanges in quality of life, sleep quality, and anxiety following tracheobronchial stenting in patients with central airway obstruction: A retrospective observational study
Central airway obstruction (CAO) severely impairs respiratory function and psychosocial well-being. This study evaluated the impact of tracheobronchial stenting on quality of life, sleep quality, and anxiety levels in patients with CAO. This retrospective observational study included 106 patients (63.2% male) who underwent tracheobronchial stenting between January and September 2024. Patients were assessed 1 day before and 1 month after the procedure using the Short Form-36, Beck Anxiety Inventory (BAI), and Pittsburgh Sleep Quality Index (PSQI). Significant improvements were observed in all Short Form-36 subscales ( P < .001), except for mental health ( P = .094). The largest improvement was observed in physical functioning, with median scores increasing from 22.5 to 80.0. Median BAI scores decreased from 38 to 22, and PSQI scores improved from 15 to 10 ( P < .001 for both). Effect size analysis demonstrated large improvements (Cohen dz = 1.110 for BAI and 1.555 for PSQI). Improvements were similar across malignant and benign (post-intubation tracheal stenosis) etiologies. Female patients demonstrated greater reductions in anxiety ( P = .005). Multivariate analysis identified age and educational level as independent predictors of anxiety change ( R 2 = 0.289, P < .001). Tracheobronchial stenting is associated with significant improvements in quality of life, sleep quality, and anxiety. These findings demonstrate that the clinical benefit of airway stenting extends beyond airway patency to include improvements in patient-centered outcomes, highlighting the importance of integrating psychosocial assessment into interventional pulmonology practice.
- Open Access
- 7 November 2026
- Published by Springer Nature in BMC Pulmonary Medicine
Long-term outcomes of COVID-19-related versus non-COVID-19-related post-intubation tracheal stenosis: a retrospective cohort study
Background: Post-intubation tracheal stenosis (PITS) is a clinically challenging condition requiring multidisciplinary bronchoscopic and surgical management. Its incidence increased markedly in recent years, particularly following the rise in patients requiring prolonged invasive mechanical ventilation (IMV) during the pandemic period. Whether the underlying etiology influences stenosis characteristics, treatment strategies, and long-term outcomes remains insufficiently understood. Methods: This retrospective, single-center cohort study included 111 patients who developed PITS following IMV between March 2020 and November 2021 and were followed for a minimum of three years. Patients were categorized by etiology: COVID-19-related ( n = 54) and non-COVID-19 ( n = 57). Demographic characteristics, stenosis features (type, grade, length, and location), bronchoscopic and surgical treatment modalities, and long-term clinical outcomes were compared between groups. Results: Baseline characteristics were largely similar between groups, except for a higher prevalence of multiple comorbidities in the non-COVID group (57.9% vs. 37.0%, p = 0.028). Intubation duration was significantly longer in the post-COVID group (21 vs. 15 days, p = 0.005). Stenosis characteristics and treatment modalities did not differ significantly between groups. At 3-year follow-up, bronchoscopic success rates (58.6% vs. 62.2%), surgical success rates (73.3% vs. 81.8%), restenosis rates (20.0% vs. 13.6%), tracheostomy dependence (9.2% vs. 5.3%), and mortality (14.8% vs. 17.5%) were all comparable between groups ( p > 0.05). Conclusion: When post-COVID and non-COVID PITS patients are compared, findings suggest that etiology may not significantly influence the long-term clinical outcomes of PITS. These findings support an individualized approach to treatment based on anatomical and clinical factors, regardless of etiology. Larger prospective multicenter studies are needed to confirm these results. Clinical trial registration: Not applicable.
- 7 November 2026
- Published by Springer Nature in BMC Pulmonary Medicine
Open AccessLong-term outcomes of COVID-19-related versus non-COVID-19-related post-intubation tracheal stenosis: a retrospective cohort study
Background: Post-intubation tracheal stenosis (PITS) is a clinically challenging condition requiring multidisciplinary bronchoscopic and surgical management. Its incidence increased markedly in recent years, particularly following the rise in patients requiring prolonged invasive mechanical ventilation (IMV) during the pandemic period. Whether the underlying etiology influences stenosis characteristics, treatment strategies, and long-term outcomes remains insufficiently understood. Methods: This retrospective, single-center cohort study included 111 patients who developed PITS following IMV between March 2020 and November 2021 and were followed for a minimum of three years. Patients were categorized by etiology: COVID-19-related ( n = 54) and non-COVID-19 ( n = 57). Demographic characteristics, stenosis features (type, grade, length, and location), bronchoscopic and surgical treatment modalities, and long-term clinical outcomes were compared between groups. Results: Baseline characteristics were largely similar between groups, except for a higher prevalence of multiple comorbidities in the non-COVID group (57.9% vs. 37.0%, p = 0.028). Intubation duration was significantly longer in the post-COVID group (21 vs. 15 days, p = 0.005). Stenosis characteristics and treatment modalities did not differ significantly between groups. At 3-year follow-up, bronchoscopic success rates (58.6% vs. 62.2%), surgical success rates (73.3% vs. 81.8%), restenosis rates (20.0% vs. 13.6%), tracheostomy dependence (9.2% vs. 5.3%), and mortality (14.8% vs. 17.5%) were all comparable between groups ( p > 0.05). Conclusion: When post-COVID and non-COVID PITS patients are compared, findings suggest that etiology may not significantly influence the long-term clinical outcomes of PITS. These findings support an individualized approach to treatment based on anatomical and clinical factors, regardless of etiology. Larger prospective multicenter studies are needed to confirm these results. Clinical trial registration: Not applicable.
- 2 October 2026
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 74 (3) , 186-190
Endobronchial vascular lesions of the lung
- 2 October 2026
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 74 (3) , 186-190
Endobronchial vascular lesions of the lung
- Open Access
- 17 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5607
Efficacy and Safety of Broncho Muco Cleaner Balloon Dilation Therapy in Chronic Bronchitis-Predominant COPD: A Prospective Interventional Study
Background/Objectives: COPD is a chronic, progressive, heterogeneous disease. While volume-reducing procedures are available for advanced emphysema-predominant COPD, options remain limited for chronic bronchitis-predominant COPD. Broncho Muco Cleaner Balloon (BMCB) dilation therapy is a method that aims to provide clinical and functional benefit by causing damage to the goblet cells in the bronchial system. This study evaluated the safety and effects of this method on exacerbations, dyspnea and exercise capacity in chronic bronchitis-predominant COPD. Methods: In this prospective interventional study, a total of 35 patients with stage II–IV chronic bronchitis-predominant COPD underwent BMCB therapy. The results of 25 patients who completed the 12-month-follow-up period were analyzed. Dyspnea was assessed using the modified Medical Research Council (mMRC) scale, pulmonary function with spirometry, exercise capacity with the 6 min walk test (6MWT), and quality of life with the St. George’s Respiratory Questionnaire (SGRQ). Results: At the 12-month follow-up, there were significant improvements in mMRC scores (p < 0.001), moderate/severe exacerbations (p = 0.022), and in the symptom, activity, impact, and total scores of the SGRQ (all p < 0.05). However, no significant changes were observed in FEV1 (p = 0.291) or 6MWT distance (p = 0.420). No procedure-related mortality occurred during the study period. In one patient, bradycardia was observed during the procedure, but it did not cause hemodynamic instability. Conclusions: Based on the results of this study, BMCB dilation therapy in patients with chronic bronchitis-predominant COPD appears to be safe. It reduces the perceived severity of dyspnea, decreases the number of moderate/severe exacerbations, and improves quality of life, without causing significant changes in pulmonary function or exercise capacity.
- 17 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (14) , 5607
Open AccessEfficacy and Safety of Broncho Muco Cleaner Balloon Dilation Therapy in Chronic Bronchitis-Predominant COPD: A Prospective Interventional Study
Background/Objectives: COPD is a chronic, progressive, heterogeneous disease. While volume-reducing procedures are available for advanced emphysema-predominant COPD, options remain limited for chronic bronchitis-predominant COPD. Broncho Muco Cleaner Balloon (BMCB) dilation therapy is a method that aims to provide clinical and functional benefit by causing damage to the goblet cells in the bronchial system. This study evaluated the safety and effects of this method on exacerbations, dyspnea and exercise capacity in chronic bronchitis-predominant COPD. Methods: In this prospective interventional study, a total of 35 patients with stage II–IV chronic bronchitis-predominant COPD underwent BMCB therapy. The results of 25 patients who completed the 12-month-follow-up period were analyzed. Dyspnea was assessed using the modified Medical Research Council (mMRC) scale, pulmonary function with spirometry, exercise capacity with the 6 min walk test (6MWT), and quality of life with the St. George’s Respiratory Questionnaire (SGRQ). Results: At the 12-month follow-up, there were significant improvements in mMRC scores (p < 0.001), moderate/severe exacerbations (p = 0.022), and in the symptom, activity, impact, and total scores of the SGRQ (all p < 0.05). However, no significant changes were observed in FEV1 (p = 0.291) or 6MWT distance (p = 0.420). No procedure-related mortality occurred during the study period. In one patient, bradycardia was observed during the procedure, but it did not cause hemodynamic instability. Conclusions: Based on the results of this study, BMCB dilation therapy in patients with chronic bronchitis-predominant COPD appears to be safe. It reduces the perceived severity of dyspnea, decreases the number of moderate/severe exacerbations, and improves quality of life, without causing significant changes in pulmonary function or exercise capacity.
- 25 June 2026
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 74 (2) , 121-125
Treatment of severe tracheobronchopathia osteochondroplastica: Application of endobronchial argon plasma coagulation, presentation of three cases and literature review
Tracheobronchopathia osteochondroplastica (TBPO) is a rare condition characterized by the abnormal growth of cartilage within the trachea and main bronchi, leading to airway obstruction. The exact cause of TBPO is unknown, but it is thought to be associated with chronic inflammation of the airways and abnormal cartilage metabolism. Since there is not a standardization, the treatment of the condition depends on disease symptoms, infection status and the severity of the airway obstruction. Here, we aimed to present three cases of severe TBPO successfully managed in our interventional pulmonology unit applying argon plasma coagulation and mechanical debulking with rigid bronchoscopy, as well as the literature review.
- 25 June 2026
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 74 (2) , 121-125
Treatment of severe tracheobronchopathia osteochondroplastica: Application of endobronchial argon plasma coagulation, presentation of three cases and literature review
Tracheobronchopathia osteochondroplastica (TBPO) is a rare condition characterized by the abnormal growth of cartilage within the trachea and main bronchi, leading to airway obstruction. The exact cause of TBPO is unknown, but it is thought to be associated with chronic inflammation of the airways and abnormal cartilage metabolism. Since there is not a standardization, the treatment of the condition depends on disease symptoms, infection status and the severity of the airway obstruction. Here, we aimed to present three cases of severe TBPO successfully managed in our interventional pulmonology unit applying argon plasma coagulation and mechanical debulking with rigid bronchoscopy, as well as the literature review.
- Open Access
- 12 January 2026
- Published by LookUs Bilisim A.S. in Medical Records
- No. 1
The Role of Interventional Bronchoscopy in the Management of Haemoptysis
Aim: Haemoptysis is a clinical condition characterised by blood in the airways and is difficult to manage even for experienced clinicians. Bronchoscopy is a crucial tool in the treatment and evaluation of haemoptysis. However, we see that it is not used sufficiently in diagnosis and treatment. Within the scope of our research, we aimed to investigate the place and importance of bronchoscopy in haemoptysis through our bronchoscopy applications in patients we follow with the diagnosis of haemoptysis. Material and Method: The files and data of patients who were admitted to the Pulmonary Diseases Department and Intensive Care Unit with the diagnosis of haemoptysis or who were followed up as outpatients and underwent bronchoscopy were retrospectively reviewed. Results: Bronchoscopy findings were normal in 18% of patients, endobronchial lesions (EBL) in 18%, external compression in 1%, mucosal-submucosal infiltration, increased raying in 4%, narrowing of orifices in 2%, mucosal petechiae-vascularity increased in 2%, fragile mucosal hyperaemia-oedema in 12%, active haemorrhage in 5%, haemoptysis residues-coagulum in 37%, and purulent secretion in 1%. While no findings were observed in 19% of the patients during bronchoscopy and no procedure was performed, 55% received topical applications, 7% received only thermal applications, and 19% received both thermal and endobronchial treatments (EBT). Conclusion: We believe that our study will support the existing literature by revealing that bronchoscopy plays an important role in the diagnosis and treatment processes of patients with haemoptysis and that this method has the potential to increase its clinical contributions in the future.
- 12 January 2026
- Published by LookUs Bilisim A.S. in Medical Records
- No. 1
Open AccessThe Role of Interventional Bronchoscopy in the Management of Haemoptysis
Aim: Haemoptysis is a clinical condition characterised by blood in the airways and is difficult to manage even for experienced clinicians. Bronchoscopy is a crucial tool in the treatment and evaluation of haemoptysis. However, we see that it is not used sufficiently in diagnosis and treatment. Within the scope of our research, we aimed to investigate the place and importance of bronchoscopy in haemoptysis through our bronchoscopy applications in patients we follow with the diagnosis of haemoptysis. Material and Method: The files and data of patients who were admitted to the Pulmonary Diseases Department and Intensive Care Unit with the diagnosis of haemoptysis or who were followed up as outpatients and underwent bronchoscopy were retrospectively reviewed. Results: Bronchoscopy findings were normal in 18% of patients, endobronchial lesions (EBL) in 18%, external compression in 1%, mucosal-submucosal infiltration, increased raying in 4%, narrowing of orifices in 2%, mucosal petechiae-vascularity increased in 2%, fragile mucosal hyperaemia-oedema in 12%, active haemorrhage in 5%, haemoptysis residues-coagulum in 37%, and purulent secretion in 1%. While no findings were observed in 19% of the patients during bronchoscopy and no procedure was performed, 55% received topical applications, 7% received only thermal applications, and 19% received both thermal and endobronchial treatments (EBT). Conclusion: We believe that our study will support the existing literature by revealing that bronchoscopy plays an important role in the diagnosis and treatment processes of patients with haemoptysis and that this method has the potential to increase its clinical contributions in the future.
- Open Access
- 1 April 2025
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 33 (2) , 217-225
The efficacy of topical mitomycin-C in the treatment of benign tracheal stenosis: A comparative study
Background: This study aims to examine the efficacy of mitomycin-C (MMC) in patients with benign tracheal stenosis who have re-stenosis requiring repeated interventional bronchoscopy. Methods: Between January 2009 and December 2019, a total of 25 patients who underwent repeated procedures for re-stenosis were retrospectively analyzed. The study group consisted of 11 patients (7 males, 4 females; median age: 37 years; range, 16 to 63 years) who underwent MMC following routine dilation and the control group consisted of 14 patients (8 males, 6 females; median age: 52 years; range, 19 to 73 years) who underwent dilation alone and did not receive MMC. Demographic data of the patients, the etiology of stenosis, comorbidities, medications used, imaging studies, location, degree and length of re-stenosis, details of interventional bronchoscopy, pre- and post-procedural time intervals between mechanical dilation, and cost were reviewed. Results: The percentage changes of re-stenosis and mean re-stenotic segment length significantly decreased (p=0.013 and p=0.029, respectively), and the medical cost (p=0.021), and number of repeated dilations (p=0.020) were lower in the MMC-treated group, compared to the control group. However, the improvement rate was not significantly different (p=0.070) between the MMC-treated group and control group. Conclusion: Mitomycin-C is helpful to decrease the tracheal re-stenosis percentage changes and the number of repeated dilations in patients with benign tracheal stenosis. It also decreases the median re-stenotic segment lengths which may be crucial for limited reserve surgery in tracheal resections. Taken together, MMC is a cost-effective, time-saving and tracheal-sparing treatment in patients with benign tracheal stenosis.
- 1 April 2025
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 33 (2) , 217-225
Open AccessThe efficacy of topical mitomycin-C in the treatment of benign tracheal stenosis: A comparative study
Background: This study aims to examine the efficacy of mitomycin-C (MMC) in patients with benign tracheal stenosis who have re-stenosis requiring repeated interventional bronchoscopy. Methods: Between January 2009 and December 2019, a total of 25 patients who underwent repeated procedures for re-stenosis were retrospectively analyzed. The study group consisted of 11 patients (7 males, 4 females; median age: 37 years; range, 16 to 63 years) who underwent MMC following routine dilation and the control group consisted of 14 patients (8 males, 6 females; median age: 52 years; range, 19 to 73 years) who underwent dilation alone and did not receive MMC. Demographic data of the patients, the etiology of stenosis, comorbidities, medications used, imaging studies, location, degree and length of re-stenosis, details of interventional bronchoscopy, pre- and post-procedural time intervals between mechanical dilation, and cost were reviewed. Results: The percentage changes of re-stenosis and mean re-stenotic segment length significantly decreased (p=0.013 and p=0.029, respectively), and the medical cost (p=0.021), and number of repeated dilations (p=0.020) were lower in the MMC-treated group, compared to the control group. However, the improvement rate was not significantly different (p=0.070) between the MMC-treated group and control group. Conclusion: Mitomycin-C is helpful to decrease the tracheal re-stenosis percentage changes and the number of repeated dilations in patients with benign tracheal stenosis. It also decreases the median re-stenotic segment lengths which may be crucial for limited reserve surgery in tracheal resections. Taken together, MMC is a cost-effective, time-saving and tracheal-sparing treatment in patients with benign tracheal stenosis.
- Open Access
- 18 February 2025
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 19 (1) , 1-7
Use of dornase alfa in the management of life-threatening mucostasis in airway stents: its efficacy and safety
Purpose: Airway stents (AS) are a last-resort treatment for central airway obstructions when airway patency cannot be maintained above 50%, in patients unsuitable for surgery, or with recurrence after surgery. However, AS placement can cause complications, including life-threatening mucostasis, which is challenging to manage. Standard methods to prevent mucus retention often have limited efficacy. Dornase alfa, a mucolytic agent widely used in cystic fibrosis (CF) patients, has shown efficacy in secretion control in mechanically ventilated pediatric non-CF patients. This study evaluates the efficacy and safety of nebulized dornase alfa in managing AS-related life-threatening mucostasis. Results: Fourteen patients (mean age 56.3 ± 15.6 years) with life-threatening mucostasis were identified among 255 stented patients (2017–2019). Eight had Y-shaped stents, and 6 had non-Y-shaped stents (5 hourglass and 1 OKI); 13 stents were placed for benign conditions and 1 for malignancy. Mucus grades (defined by Marchese et al.) and the number of bronchoscopies needed 6 months before and after dornase alfa were evaluated. Statistically significant decreases were observed in both mucus grades (2.36 ± 0.49 to 0.79 ± 0.59, p < 0.001) and the number of bronchoscopies per patient (3.21 ± 0.89 to 2.00 ± 1.04, p = 0.002). The shape of AS and the presence of bronchiectasis on thoracic computed tomography scans had no significant impact on mucostasis development. No side effects related to dornase alfa were observed. Conclusion: Dornase alfa significantly reduced mucus burden and bronchoscopic interventions in AS-related life-threatening mucostasis, demonstrating its safety and efficacy for managing this complication.
- 18 February 2025
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 19 (1) , 1-7
Open AccessUse of dornase alfa in the management of life-threatening mucostasis in airway stents: its efficacy and safety
Purpose: Airway stents (AS) are a last-resort treatment for central airway obstructions when airway patency cannot be maintained above 50%, in patients unsuitable for surgery, or with recurrence after surgery. However, AS placement can cause complications, including life-threatening mucostasis, which is challenging to manage. Standard methods to prevent mucus retention often have limited efficacy. Dornase alfa, a mucolytic agent widely used in cystic fibrosis (CF) patients, has shown efficacy in secretion control in mechanically ventilated pediatric non-CF patients. This study evaluates the efficacy and safety of nebulized dornase alfa in managing AS-related life-threatening mucostasis. Results: Fourteen patients (mean age 56.3 ± 15.6 years) with life-threatening mucostasis were identified among 255 stented patients (2017–2019). Eight had Y-shaped stents, and 6 had non-Y-shaped stents (5 hourglass and 1 OKI); 13 stents were placed for benign conditions and 1 for malignancy. Mucus grades (defined by Marchese et al.) and the number of bronchoscopies needed 6 months before and after dornase alfa were evaluated. Statistically significant decreases were observed in both mucus grades (2.36 ± 0.49 to 0.79 ± 0.59, p < 0.001) and the number of bronchoscopies per patient (3.21 ± 0.89 to 2.00 ± 1.04, p = 0.002). The shape of AS and the presence of bronchiectasis on thoracic computed tomography scans had no significant impact on mucostasis development. No side effects related to dornase alfa were observed. Conclusion: Dornase alfa significantly reduced mucus burden and bronchoscopic interventions in AS-related life-threatening mucostasis, demonstrating its safety and efficacy for managing this complication.
- Open Access
- 8 November 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (45) , e40535
A descriptive analysis of 21 patients with pulmonary amyloidosis: An observational study
Pulmonary amyloidosis is an extremely rare disease, often detected incidentally because of its asymptomatic nature and potential to result in fatal outcomes. In this study, we aimed to present the clinical and radiological features of patients diagnosed with pulmonary amyloidosis by biopsy. This descriptive study included 21 patients with pathologically diagnosed pulmonary amyloidosis. Pulmonary amyloidosis was classified as diffuse alveolar-septal amyloidosis (DASA), cystic amyloidosis (CPA), tracheobronchial amyloidosis (TBA), nodular amyloidosis (NPA), and extraparenchymal pulmonary amyloidosis (pleural and mediastinal lymph node). Clinical, bronchoscopic, and radiological specific characteristics were presented in detail to be used for differential diagnosis. The median age of the patients was 63 (40–83) years, and 14 (66.7%) were male. Twenty patients (95.2%) presented with at least 1 comorbidity. All patients diagnosed with tracheobronchial amyloidosis were symptomatic at presentation, whereas those diagnosed with NPA/extraparenchymal amyloidosis were often asymptomatic. The patients included 1 case of DASA, 1 case of CPA, 10 cases of NPA, 6 cases of TBA, and 3 cases of extraparenchymal amyloidosis involving the mediastinal lymph node and pleura. Sixteen patients (76.2%) were classified as localized amyloidosis, while 5 patients (23.8%) were classified as systemic amyloidosis following the diagnosis of multiple myeloma, monoclonal gammopathy of undetermined significance, systemic lupus erythematosus, Sjogren’s syndrome, and B-cell lymphoma. Bronchoscopic biopsies were sufficient for diagnosis, and notably, even transbronchial needle aspiration could be a useful diagnostic method. During the follow-up, we observed that the disease remained stable without progression. However, it is important to note that patients with concurrent malignancies experience fatal outcomes. In conclusion, it is crucial to distinguish pulmonary amyloidosis from other pulmonary diseases such as malignancies, infectious diseases, and interstitial lung diseases, which may have similar clinical and radiological findings. Bronchoscopic diagnostic methods are usually sufficient for the diagnosis. Although patients with pulmonary involvement mostly remain stable during long-term follow-up without progression, it is important to consider the risk of malignancy.
- 8 November 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (45) , e40535
Open AccessA descriptive analysis of 21 patients with pulmonary amyloidosis: An observational study
Pulmonary amyloidosis is an extremely rare disease, often detected incidentally because of its asymptomatic nature and potential to result in fatal outcomes. In this study, we aimed to present the clinical and radiological features of patients diagnosed with pulmonary amyloidosis by biopsy. This descriptive study included 21 patients with pathologically diagnosed pulmonary amyloidosis. Pulmonary amyloidosis was classified as diffuse alveolar-septal amyloidosis (DASA), cystic amyloidosis (CPA), tracheobronchial amyloidosis (TBA), nodular amyloidosis (NPA), and extraparenchymal pulmonary amyloidosis (pleural and mediastinal lymph node). Clinical, bronchoscopic, and radiological specific characteristics were presented in detail to be used for differential diagnosis. The median age of the patients was 63 (40–83) years, and 14 (66.7%) were male. Twenty patients (95.2%) presented with at least 1 comorbidity. All patients diagnosed with tracheobronchial amyloidosis were symptomatic at presentation, whereas those diagnosed with NPA/extraparenchymal amyloidosis were often asymptomatic. The patients included 1 case of DASA, 1 case of CPA, 10 cases of NPA, 6 cases of TBA, and 3 cases of extraparenchymal amyloidosis involving the mediastinal lymph node and pleura. Sixteen patients (76.2%) were classified as localized amyloidosis, while 5 patients (23.8%) were classified as systemic amyloidosis following the diagnosis of multiple myeloma, monoclonal gammopathy of undetermined significance, systemic lupus erythematosus, Sjogren’s syndrome, and B-cell lymphoma. Bronchoscopic biopsies were sufficient for diagnosis, and notably, even transbronchial needle aspiration could be a useful diagnostic method. During the follow-up, we observed that the disease remained stable without progression. However, it is important to note that patients with concurrent malignancies experience fatal outcomes. In conclusion, it is crucial to distinguish pulmonary amyloidosis from other pulmonary diseases such as malignancies, infectious diseases, and interstitial lung diseases, which may have similar clinical and radiological findings. Bronchoscopic diagnostic methods are usually sufficient for the diagnosis. Although patients with pulmonary involvement mostly remain stable during long-term follow-up without progression, it is important to consider the risk of malignancy.